Logotype for Bayer AG

Bayer (BAYN) investor relations material

Bayer Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Bayer AG
Q3 2026 earnings summary3 Nov, 2026

Executive summary

  • Q3 sales rose 4.1% reported to €10.053bn and 1.9% currency- and portfolio-adjusted; EBITDA before special items increased 6.9% to €1.615bn.

  • Pharmaceuticals drove growth, while Crop Science and Consumer Health faced pressure; full-year guidance rose for EBITDA, free cash flow, net financial debt and Pharma margin.

Financial highlights

  • Q3 net income was -€672m and core EPS fell 36.7% to €0.31; free cash flow was -€293m, including €1.121bn of net legal-proceeding outflows.

  • Nine-month sales were €34.330bn, up 2.9% currency- and portfolio-adjusted; EBITDA before special items rose 6.6% to €8.212bn and core EPS was €3.97.

  • Nine-month free cash flow was -€3.0bn, including €3.7bn of litigation payouts; net financial debt declined to €31.083bn, supported by the €3.0bn Apollo contribution.

Outlook and guidance

  • FY2026 currency-adjusted EBITDA before special items guidance rose to €9.8–10.3bn from €9.6–10.1bn; core EPS guidance remained €4.30–4.80.

  • Free cash flow guidance improved to -€1.5bn to -€0.5bn, including €5bn of litigation payouts; year-end net financial debt guidance fell to €28–29bn.

  • Pharma margin guidance increased to 25–27% from 23–25%, with sales growth expected toward the upper end of its 0–3% range; Crop Science and Consumer Health market outlooks were lowered.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Bayer earnings date

Logotype for Bayer AG
Q4 202624 Feb, 2027
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Bayer earnings date

Logotype for Bayer AG
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Bayer AG operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The company researches, develops, manufactures, and markets prescription products primarily for the areas of cardiology and women's healthcare; and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. It is also involved in developing over-the-counter medications and dietary supplements.